DOCSLIB.ORG

A Round-Up of ASCO's 2013-2014 Guideline Releases, Updates, And

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
A Round-Up of ASCO's 2013-2014 Guideline Releases, Updates, And CommunityFeature Report JOURNAL CLUB A round-up of ASCO’s 2013-2014 guideline releases, updates, and endorsements Bernard A Mason, MD uring the past year, the American Society colon cancer treatment outside of a clinical trial of Clinical Oncology (ASCO) has pub- because of lack of evidence and the danger of false Dlished 7 special articles that create, update, positives. Likewise, the routine chest X-ray has lit- or endorse clinical practice guidelines. All 7 articles tle use when CT scans of the chest are being done are the subject of this month’s review. periodically. Routine laboratory studies other than the car- Follow-up care, surveillance, and cinoembryonic antigen (CEA) blood test, such as secondary prevention measures for CBC and liver function tests have not been rec- survivors of colorectal cancer1, 2 ommended since before 2005. Finally, the current Since 2006, ASCO has adopted a policy of endors- guidelines recommend secondary prevention eforts ing clinical practice guidelines developed by oth- such as maintaining body weight, physical activity, ers in order to increase the number of such guide- and a healthy diet, although there is little high-qual- lines available for ASCO membership. Recently, ity evidence for these behaviors. the society endorsed the guidelines for colon can- cer follow-up created by the Cancer Care Ontario Answer: d (CCO). Tese guidelines include surveillance rec- ommendations that are very similar to the 2005 Sentinel lymph node biopsy for women ASCO guidelines and the current NCCN guide- with early-stage breast cancer3,4 lines, with a few minor diferences. However, unlike Since the 2005 ASCO guidelines for sentinel node NCCN and previous ASCO guidelines, the current biopsy were published, there have been 9 random- guidelines include statements about secondary pre- ized clinical trials and 13 cohort studies pertinent to vention, written survivorship plans for the patient’s the issue of sentinel node biopsy (SLB) and axillary other providers, and the futility of surveillance tests node dissection (ALND) available for expert panel in patients who are not candidates for surgery or review. Te current version includes some changes systemic therapy due to comorbid disease. in the standard of care. A direct comparison of the 2005 and 2014 recommendations is online. Which of the following was specifcally recommended in the endorsed CCO guidelines Sentinel node biopsy should be ofered to women for the follow-up care of patients with colon with breast cancer in the following circumstances: cancer: a) Operable breast cancer and multicentric disease a) PET/CT chest, abdomen, and pelvis annually b) Large or locally advanced breast cancer b) Complete blood count (CBC) and liver function c) Pregnant women with breast cancer tests d) DCIS in women undergoing breast conservation c) Chest X-ray and radiation therapy d) Maintaining healthy body weight, physical activ- ity, and eating a healthy diet Axillary lymph node dissection should be performed in: Key points a) Women with 1-2 sentinel lymph nodes who are Te current ASCO-endorsed guidelines (as well being treated with breast conservation and whole as those of the NCCN) specifcally recommend breast radiation therapy. against the use of PET scans for surveillance after b) Women without sentinel node metastases. JCSO 2014;12:421-424. ©2014 Frontline Medical Communications. DOI 10.12788/jcso.0090. Volume 12/Number 11 November 2014 J THE JOURNAL OF COMMUNITY AND SUPPORTIVE ONCOLOGY 421 Features c) Women with sentinel node metastases who are being twofold increase in breast cancer recurrence which is not treated with mastectomy. improved by a boost of radiation therapy, systemic adju- d) Women with DCIS vant therapy, or clinical factors such as favorable biology. Moreover, results are not improved by re-excising for wider Key points margins compared to negative margins as defned by no According to the guidelines, women may be not be candi- ink on tumor. Tis applies to patients who are younger dates for SLB if they have DCIS and are undergoing breast than 40, those with increased intraductal component to conservation and radiation therapy, because of a lack of evi- the tumor, and those with higher grade tumors biologi- dence about its efcacy and concerns about lymphedema. cally. Implementation of these new guidelines will result in Likewise, there is insufcient evidence to justify SLB in a decrease in re-excision rates, which will improve cosmetic women with large and locally advanced invasive tumors, results, and a reduction in overall health care costs. infammatory breast cancer, and in pregnancy. However, there is moderately strong evidence to support SLB in Answer: a only women with multicentric tumors. Review of the literature and analysis has led to strong Adjuvant endocrine therapy for women with recommendations for not performing ALND in women hormone receptor–positive breast cancer8-11 with negative SLB, in those with DCIS, and even in In late May 2014, the Journal of Clinical Oncology those with 1 or 2 SLN metastases, based on recent trials. published a focused update of the previous guidelines and However, ALND is recommended in women being treated updates that had been published in 2002, 2003, 2004, and with mastectomy who had positive SLB. 2010. However, even this, the most recent guideline for adjuvant endocrine therapy of early breast cancer, is already Answers: a and c, respectively somewhat out of date because of recent data. Te early results of the SOFT/TEXT trials presented at ASCO Margins for breast-conserving surgery with 2014 and recently published, provided a new option for whole-breast irradiation in stage I and II premenopausal women – exemestane plus ovarian ablation. invasive breast cancer5-7 A multidisciplinary consensus panel review reviewed data According to the guidelines, which of the following is from 33 studies comprising 28,162 patients and analyzed not currently a recommended adjuvant hormonal the surgical margin and its relationship to the develop- therapy for a menopausal woman: ment of ipsilateral breast cancer recurrence. Te consensus a) Tamoxifen for 10 years guideline developed by the Society of Surgical Oncology b) Aromatase inhibitor for 5 years and the American Society for Radiation Oncology was c) Tamoxifen for 5 years, followed by an aromatase inhibi- endorsed by ASCO. Te results are practice changing, and tor for 5 years this new standard for the adequate margin for invasive can- d) Tamoxifen for 2-3 years, followed by an aromatase cer should reduce re-excision rates and health care costs, as inhibitor for up to 5 years for up to a total of 8 years well as improve overall cosmetic results. e) Aromatase inhibitor for 10 years Surgical margins for the lumpectomy specimen for Key points women undergoing breast-conserving surgery with For postmenopausal women, the guideline recommenda- whole-breast radiation should be (include all that are tions have changed since the publication of the ATLAS correct): trial earlier this year. For women who received tamoxi- a) No ink on tumor fen for an initial 5-year course, a decision must be made b) 2 mm as to whether to administer another 5 years of tamoxifen c) Wider in younger women, especially under age 30 or switch the patient to an aromatase inhibitor for 5 years. d) Wider margins for extensive intraductal component to Either course of action is acceptable according to the new the cancer guidelines. For those women who had already received tamoxifen for 2-3 years, aromatase inhibitor may be given Key points for up to 5 years, for a total of up to 8 years of endocrine For women choosing breast conserving surgery with therapy. whole breast irradiation instead of modifed radical mas- Tere are insufcient data to recommend an aromatase tectomy, the surgical margin may be a determining factor inhibitor for longer than 5 years, either as initial therapy or in the risk of ipsilateral breast cancer recurrence. A posi- following tamoxifen. For patients who begin their therapy tive margin, defned as ink on tumor, is associated with a with an aromatase inhibitor, but are intolerant and cannot 422 THE JOURNAL OF COMMUNITY AND SUPPORTIVE ONCOLOGY g November 2014 www.jcso-online.com JOURNAL CLUB complete 5 years, tamoxifen may be given to complete a ASCO panel found no evidence for the efcacy of any total of 5 years. neuroprotective agents, although there was intriguing evi- dence for a beneft for venlafaxine from a small study, but Answer, e not enough to recommend yet. Larger trials of this agent were recommended. For treatment of existing neuropathy Screening, assessment, and management of only duloxetine could be recommended, particularly for fatigue in adult survivors of cancer12 oxaliplatin neuropathy. Calcium and magnesium infusions Most cancer patients will experience fatigue during their were thought to protect from neuropathy in early studies, treatment, and almost one-third will continue to com- but subsequent confrmatory trials were negative. Acetyl-L plain for years after treatment. For the current ASCO carnitine and lamotrigine have been found to have no ben- fatigue guideline, adaptation methodology was used to eft in phase 3 studies. adapt already existing guidelines from the pan-Canadian and NCCN guidelines for screening, assessment and care Answer: a of cancer-related fatigue plus the NCCN guidelines for survivorship. Systemic therapy for patients with advanced human epidermal growth factor receptor Which of the following does not reduce fatigue in 2-positive breast cancer14 cancer survivors? ASCO has created a new guideline for the treatment of a) Modafnil metastatic disease in the HER2-positive patient, and b) Mindfulness-based intervention includes recommendations based on data for newer agents c) Cognitive behavior therapy that have been recently approved including pertuzumab d) Maintaining physical activity and emtansine (T-DM1). New frst-, second-, and third- line recommendations are ofered, as well as guidance about Key points the use of hormone therapy in such patients.
Load more

Recommended publications
  • Understanding Surgery a Guide for People with Cancer, Their Families and Friends
    Understanding Surgery A guide for people with cancer, their families and friends Treatment For information & support, call Understanding Surgery A guide for people with cancer, their families and friends First published April 2014. This edition April 2019. © Cancer Council Australia 2019. ISBN 978 1 925651 47 8 Understanding Surgery is reviewed approximately every three years. Check the publication date above to ensure this copy is up to date. Editor: Ruth Sheard. Designer: Eleonora Pelosi. Printer: SOS Print + Media Group. Acknowledgements This edition has been developed by Cancer Council NSW on behalf of all other state and territory Cancer Councils as part of a National Cancer Information Subcommittee initiative. We thank the reviewers of this booklet: Prof Andrew Spillane, Surgical Oncologist, Melanoma Institute of Australia, and Professor of Surgical Oncology, The University of Sydney Northern Clinical School, NSW; Lynne Hendrick, Consumer; Judy Holland, Physiotherapist, Calvary Mater Newcastle, NSW; Kara Hutchinson, Cancer Nurse Coordinator, St Vincent’s Hospital Melbourne, VIC; A/Prof Declan Murphy, Urologist and Director of Genitourinary Oncology, Peter MacCallum Cancer Centre, VIC; Caitriona Nienaber, 13 11 20 Consultant, Cancer Council WA; Prof Stephan Schug, Director of Pain Medicine, Royal Perth Hospital, and Chair of Anaesthesiology and Pain Medicine, The University of Western Australia Medical School, WA; Dr Emma Secomb, Specialist Surgeon, Hinterland Surgical Centre, QLD. We would like to thank the health professionals, consumers and editorial teams who have worked on previous editions of this title. This booklet is funded through the generosity of the people of Australia. Note to reader Always consult your doctor about matters that affect your health.
    [Show full text]
  • Complex General Surgical Oncology
    ACGME Program Requirements for Graduate Medical Education in Complex General Surgical Oncology ACGME-approved focused revision: February 3, 2020; effective July 1, 2020 Contents Introduction .............................................................................................................................. 3 Int.A. Preamble ................................................................................................................ 3 Int.B. Definition of Subspecialty ..................................................................................... 4 Int.C. Length of Educational Program ............................................................................ 4 I. Oversight ............................................................................................................................ 4 I.A. Sponsoring Institution............................................................................................ 4 I.B. Participating Sites .................................................................................................. 4 I.C. Recruitment ............................................................................................................. 6 I.D. Resources ............................................................................................................... 6 I.E. Other Learners and Other Care Providers ............................................................ 7 II. Personnel ...........................................................................................................................
    [Show full text]
  • Surgical Oncology 3 PGY3
    Stanford University General Surgery Residency Program Surgical Oncology 3 / Endocrine Surgery Rotation Goals and Objectives Rotation Director: Dana Lin, MD Description The Surgical Oncology 3 / Endocrine Surgery rotation offers an intensive experience in the surgical care of patients with endocrine diseases as well as breast cancer and melanoma. Goals The goal of the Surgical Oncology 3 / Endocrine Surgery rotation is to: Gain the knowledge and experience in the evaluation and management of patients with endocrine diseases, breast cancer, and melanoma. The primary goals for the R-3 resident: Develop knowledge and experience in the evaluation and management of patients with endocrine diseases, breast cancer, and melanoma. Acquire and refine procedural and operative skills required in the care of these patients. Direct the post-operative / in-patient care of the patients on the service. Objectives The Surgical Oncology 3/ Endocrine Surgery R-3 rotation has the following objectives: The resident has primary responsibility for the management of all patients admitted to or evaluated by the team in conjunction with the attending surgeon. The R-3 gains knowledge of surgical care through discussion with and teaching from the attending physicians in the inpatient and outpatient setting, attendance at the multidisciplinary endocrine tumor board conference, as well as independent reading. The resident gains operative skills through pre-operative reading and preparation and by direct intra-operative teaching and guidance from the faculty. Residents can expect frequent teaching from members of the team, both at the bedside and during formal and informal sessions. Feedback and teaching is individualized to the needs of the residents.
    [Show full text]
  • Tumor Registrar Vocabulary: the Composition of Medical Terms Book Three
    SEER Program Self InstructionalManual for Cancer Registrars Tumor Registrar Vocabulary: The Composition of Medical Terms Book Three Second Edition U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES Public Health Service National institutesof Health SEER PROGRAM SELF-INSTRUCTIONAL MANUAL FOR CANCER REGISWRARS Book 3 - CANCER REGISTRAR VOCABULARY: THE COMPOSITION OF MEDICAL TERMS Second Edition Originally Preparedfor the Louisiana Regional Medical Program Under the Direction of: C. Dennis Fink, Ph.D., Program Director, HumRRO Robert F. Ryan, M.D., Technical Advisor, Tulane University Revised by: SEER Program Cancer Statistics Branch, National Cancer Institute Editor-in-Chief: Evelyn M. Shambaugh, M.A., CTR Cancer Statistics Branch, National Cancer Institute Assisted by Self-InstructionalManual Committee: Dr. Robert F. Ryan, EmeritusProfessor of Surgery Tulane University School of Medicine New Orleans, Louisiana Mildred Weiss Ruth Navotny Mary A. Kruse LOs Angeles, California San Francisco, California Bethesda, Maryland BOOK 3 CANCER REGISTRAR VOCABULARY: THE COMPOSITION OF MEDICAL TERMS TABLE OF CONTENTS BOOK 3: CANCER REGISTRAR VOCABULARY: THE COMPOSITION OF MEDICAL TERMS Page Section A--Objectives and Content of Book 3 ................................... 1 Section B--Word Roots, Suffixes, and Prefixes ................................... 5 Section C--Common Symptomatic Suffixes ..................................... 31 Section D--Common Diagnostic Suffixes ....................................... 63 Section E--Cancer Registrar Vocabulary: Complaints
    [Show full text]
  • Gynecologic Oncology
    GYNECOLOGIC ONCOLOGY 2018 SAUDI FELLOWSHIP GYNECOLOGIC ONCOLOGY PROGRAM SAUDI FELLOWSHIP GYNECOLOGIC-ONCOLOGY CURRICULUM PREPARATION Curriculum Scientific Group DR. HANY SALEM DR. ISMAIL ALBADAWI DR. MOHAMMAD ALSHEHRI SUPERVISION Curriculum Specialists PROF. ZUBAIR AMIN DR. SAMI ALSHAMARRI REVIEW AND APPROVAL Scientific Council DR. HANY SALEM DR. ISMAIL ALBADAWI DR. MOHAMMAD ALSHEHRI DR. MOHAMMAD ADDAR DR. ABDULAZIZ AL-OBAID SAUDI FELLOWSHIP GYNE-ONCOLOGY CURRICULUM 1 COPYRIGHTS AND AMENDMENTS All rights reserved. © 2018 Saudi Commission for Health Specialties. This material may not be reproduced, displayed, modified, distributed, or used in any other manner without prior written permission of the Saudi Commission for Health Specialties, Riyadh, Kingdom of Saudi Arabia. Any amendment to this document shall be approved by the Specialty Scientific Council and the Executive Council of the commission and shall be considered effective from the date the updated electronic version of this curriculum was published on the commission Web site, unless a different implementation date has been mentioned. Correspondence: Saudi Commission for Health Specialties P.O. Box: 94656 Postal Code: 11614 Contact Center: 920019393 E-mail: [email protected] Website: www.scfhs.org.sa Formatted and Designed by: Manoj Thomas Varghese, CMT (SCFHS) 2 SAUDI FELLOWSHIP GYNE-ONCOLOGY CURRICULUM ACKNOWLEDGEMENTS The Gynecologic Oncology Fellowship Training team acknowledges the valuable contributions and feedback from the scientific committee members in the development of this program. We extend special appreciation and gratitude to all the members who have been pivotal in the completion of this booklet, especially the Scientific Council, Curriculum Group, and the Curriculum Specialists. We would also like to acknowledge that the CanMEDS framework is a copyright of the Royal College of Physicians and Surgeons of Canada, and many of the descriptions and competencies have been acquired from their resources.
    [Show full text]
  • Clinical and Genome-Wide Analysis of Cisplatin-Induced Peripheral Neuropathy in Survivors of Adult-Onset Cancer M
    Published OnlineFirst June 13, 2017; DOI: 10.1158/1078-0432.CCR-16-3224 Personalized Medicine and Imaging Clinical Cancer Research Clinical and Genome-Wide Analysis of Cisplatin-Induced Peripheral Neuropathy in Survivors of Adult-Onset Cancer M. Eileen Dolan1, Omar El Charif1, Heather E. Wheeler2, Eric R. Gamazon3, Shirin Ardeshir-Rouhani-Fard4, Patrick Monahan4, Darren R. Feldman5, Robert J. Hamilton6, David J. Vaughn7, Clair J. Beard8, Chunkit Fung9, Jeri Kim10, Sophie D. Fossa11, Daniel L Hertz12, Taisei Mushiroda13, Michiaki Kubo13, Lawrence H. Einhorn4, Nancy J. Cox3, and Lois B. Travis4; for the Platinum Study Group Abstract Purpose: Our purpose was to characterize the clinical influ- Results: Eight sensory items formed a subscale with good ences, genetic risk factors, and gene mechanisms contributing to internal consistency (Cronbach a ¼ 0.88). Variables signifi- persistent cisplatin-induced peripheral neuropathy (CisIPN) in cantly associated with CisIPN included age at diagnosis (OR À testicular cancer survivors (TCSs). per year, 1.06; P ¼ 2 Â 10 9), smoking (OR, 1.54; P ¼ 0.004), Experimental Design: TCS given cisplatin-based therapy com- excess drinking (OR, 1.83; P ¼ 0.007), and hypertension pleted the validated EORTC QLQ-CIPN20 questionnaire. An (OR, 1.61; P ¼ 0.03). CisIPN was correlated with lower À ordinal CisIPN phenotype was derived, and associations with self-reported health (OR, 0.56; P ¼ 2.6 Â 10 9) and weight age, smoking, excess drinking, hypertension, body mass index, gain adjusted for years since treatment (OR per Dkg/m2, diabetes, hypercholesterolemia, cumulative cisplatin dose, and 1.05; P ¼ 0.004). PrediXcan identified lower expres- self-reported health were examined for 680 TCS.
    [Show full text]
  • European Society of Gynaecological Oncology Quality Indicators for Surgical Treatment of Cervical Cancer
    Original research Int J Gynecol Cancer: first published as 10.1136/ijgc-2019-000878 on 3 January 2020. Downloaded from European Society of Gynaecological Oncology quality indicators for surgical treatment of cervical cancer David Cibula,1 François Planchamp,2 Daniela Fischerova,1 Christina Fotopoulou,3 Christhardt Kohler,4 Fabio Landoni,5 Patrice Mathevet,6 Raj Naik,7 Jordi Ponce,8 Francesco Raspagliesi,9 Alexandros Rodolakis,10 Karl Tamussino,11 Cagatay Taskiran,12 Ignace Vergote,13 Pauline Wimberger,14 Ane Gerda Zahl Eriksson,15 Denis Querleu2 For numbered affiliations see ABSTRACT as a component of comprehensive multi- disciplinary end of article. Background Optimizing and ensuring the quality of management has been shown to improve outcomes 3 4 surgical care is essential to improve the management and in patients with other types of malignancies. Imple- Correspondence to outcome of patients with cervical cancer. mentation of a quality improvement program helped Dr David Cibula, Department OBJECTIVE to reduce both morbidity and costs in other tumors of Obstetrics and Gynecology, University of Prague, 110 To develop a list of quality indicators for surgical treatment where surgical interventions are also high risk. Thus, 00 Staré Město, Czechia; d_ of cervical cancer that can be used to audit and improve it is likely that implementation of a quality manage- cibula@ yahoo. com clinical practice. ment program could improve survival of patients with Methods Quality indicators were developed using a cervical cancer. four- step evaluation process that included a systematic The aim of this project was to develop a list of Received 30 August 2019 literature search to identify potential quality indicators, Revised 17 October 2019 quality indicators for surgical treatment of cervical in- person meetings of an ad hoc group of international Accepted 22 October 2019 cancer that can be used to audit and improve clin- experts, an internal validation process, and external review by a large panel of European clinicians and patient ical practice in an easy and practicable way.
    [Show full text]
  • Standards for Oncology Registry Entry STORE 2018
    STandards for Oncology Registry Entry STORE 2018 Effective for Cases Diagnosed January 1, 2018 STORE STandards for Oncology Registry Entry Released 2018 (Incorporates all updates to Commission on Cancer, National Cancer Database Data standards since FORDS was revised in 2016) Effective for cases diagnosed January 1, 2018 See Appendix A for Updates since FORDS: Revised for 2016. Version 1.0 © 2018 AMERICAN COLLEGE OF SURGEONS All Rights Reserved STORE 2018 Table of Contents Table of Contents Table of Contents ......................................................................................................................... ii Foreword ..................................................................................................................................... 1 FROM “FORDS” TO “STORE” ..................................................................................................................... 1 Preface 2018 ................................................................................................................................ 2 Comorbidities and Complications ............................................................................................................. 2 Revisions to Staging Requirements ........................................................................................................... 2 Staging Data Items No Longer Required for Cases Diagnosed in 2018 and Later (Required for Cases Diagnosed 2017 and Earlier) ................................................................................................................
    [Show full text]
  • GUIDELINES for COMPETENCY BASED POSTGRADUATE TRAINING PROGRAMME for Mch in GYNAECOLOGICAL ONCOLOGY SUBJECT SPECIFIC OBJECTIVES
    GUIDELINES FOR COMPETENCY BASED POSTGRADUATE TRAINING PROGRAMME FOR MCh IN GYNAECOLOGICAL ONCOLOGY Preamble Gynaecological Cancers (Cancer cervix, cancer uterus, tubo-ovarian cancers, vaginal and vulval cancers) comprise 25-40% of patient workload in established Departments of Radiation Oncology, Medical Oncology and Surgical Oncology. Whereas specialities such as radiation oncology and medical oncology look after all cancers, there is lack of specialists interested or devoted to the field of “Gynaecological Oncology”. A subspecialist in Gynaecological Oncology is one who has undertaken formal training in field of Gynaecological oncology and acquires special expertise in the field of Gynaecological Oncology including broad based knowledge in related disciplines such as medical oncology, radiation oncology, gynaecological pathology and palliative management of patients suffering from gynaecological cancers. SUBJECT SPECIFIC OBJECTIVES The aims of Sub-specialisation in Gynaecological Oncology are: • To create a work force of specialists trained in the field of Gynaecological Oncology. • To improve practice, knowledge and research in the field of Gynaecological Oncology. • To improve standards of care for patients suffering from gynaecological cancers. • To encourage close understanding with disciplines such as Radiation Oncology and Medical Oncology involved in the care of women suffering from gynaecological cancer. • To encourage co-ordinated management of gynaecological cancers as a multidisciplinary approach. SUBJECT SPECIFIC COMPETENCIES By the end of the course, the student should have acquired knowledge (cognitive domain), professionalism (affective domain) and skills (psychomotor domain) as per details given below: 1 A. Cognitive domain (theoretical knowledge): The post graduate student should acquire knowledge in the following areas by the end of the training programme. Thorough understanding of: .
    [Show full text]
  • Cancer Surgeries in the Time of COVID-19: a Message from the SSO President and President-Elect
    Cancer Surgeries in the Time of COVID-19: A Message from the SSO President and President-Elect March 23, 2020 Dear SSO Members, In these unprecedented times, we are forced to consider triage and rationing of cancer surgery cases. Here are a few of the reasons: • the potential shortage of supplies, such as masks, gowns, gloves • the potential shortage of hospital personnel due to sickness, quarantine and duties at home • the potential shortage of hospital beds, ICU beds and ventilators • the desire to maximize social distancing amongst our patients, colleagues and staff. We have asked each of the SSO Disease Site Work Group Chairs and Vice Chairs to provide their recommendations for managing care in their specialties, assuming a 3- to 6-month delay in care. We have summarized their recommendations below. Numerous organizations are publishing in-depth guidelines, such as the NCCN, ACS, and ASCO, and we will provide links to those documents on the SSO Website. We have also instituted a COVID-19 community discussion page in My SSO Community for members to share what is happening in their institutions. In the next few days, SSO will produce a series of podcasts featuring discussions with experts, regarding their opinions and institutional practices. These podcasts will be available on SSO’s Website, iTunes, Sticher and other podcast platforms. Please watch your email and SSO’s Twitter and Facebook pages for details. The Annals of Surgical Oncology will be publishing an editorial on this topic soon. As each institution across the world is experiencing this pandemic at different levels, the timing of rationing care will vary and must be decided locally.
    [Show full text]
  • Current Approaches to Skin Cancer Management in Organ Transplant Recipients Meena K
    Current Approaches to Skin Cancer Management in Organ Transplant Recipients Meena K. Singh, MD,* and Jerry D. Brewer, MD† Approximately 225,000 people are living with organ transplants in the United States. Organ transplant recipients have a greater risk of developing skin cancer, including basal cell carcinoma, squamous cell carcinoma, and malignant melanoma, with an approximately 250 times greater incidence of squamous cell carcinoma in certain transplant recipients, compared with the general population. Because skin cancers are the most common posttransplant malignancy, the resultant morbidity and mortality in these high-risk patients is quite significant. Semin Cutan Med Surg 30:35-47 © 2011 Elsevier Inc. All rights reserved. pproximately 225,000 people are living with organ violet B radiation induces direct DNA damage and indirectly Atransplants in the United States. Organ transplant recip- causes DNA damage through production of reactive oxygen ients (OTRs) are at increased risk for both cutaneous and species.6 UVR also promotes the development of skin cancer systemic malignancy. More than 1000 articles in the medical through cutaneous immunosuppression.7 literature discuss cancer in the setting of organ transplanta- The immunosuppressive regimen required for graft sur- tion, most of which focus on skin cancer. vival in OTRs may lead to an impaired immune surveillance Skin cancer is the most common human malignancy, with system, which may influence the development of skin can- approximately 3.5 million skin cancers diagnosed annually cers. Certain immunosuppressive agents may also promote in the United States.1 Nonmelanoma skin cancer (NMSC) is malignancy through direct carcinogenesis.8-10 Skin cancer in the most common type, with approximately 2.8 million basal the setting of organ transplantation is also influenced by hu- cell carcinomas and more than 700,000 squamous cell car- man papillomavirus carcinogenesis, cancer susceptibility cinomas (SCCs) diagnosed each year.
    [Show full text]
  • The Surgeon and the Patient with Cancer: the Development of Surgical Oncology
    Henry Ford Hospital Medical Journal Volume 30 Number 3 Article 11 9-1982 The Surgeon and the Patient with Cancer: The Development of Surgical Oncology Angelos A. Kambouris Follow this and additional works at: https://scholarlycommons.henryford.com/hfhmedjournal Part of the Life Sciences Commons, Medical Specialties Commons, and the Public Health Commons Recommended Citation Kambouris, Angelos A. (1982) "The Surgeon and the Patient with Cancer: The Development of Surgical Oncology," Henry Ford Hospital Medical Journal : Vol. 30 : No. 3 , 156-159. Available at: https://scholarlycommons.henryford.com/hfhmedjournal/vol30/iss3/11 This Article is brought to you for free and open access by Henry Ford Health System Scholarly Commons. It has been accepted for inclusion in Henry Ford Hospital Medical Journal by an authorized editor of Henry Ford Health System Scholarly Commons. Henry Ford Hosp Med J Vol 30, No 3,1982 Sjf]iii;^c:iciiil ,iAijr'III:icic The Surgeon and the Patient with Cancer: The Development of Surgical Oncology Angelos A. Kambouris, MD* The role ofthe surgeon in treating patients with cancer to become familiar with radiotherapy, its capabilities has changed over the past 30 years. For many years the and its side effects, in order to serve the best interests of surgeon was traditionally viewed as the key clinician in their patients. Cooperative teams of surgeons and radio­ treating cancer. This role was strengthened by the therapists were established, and as the results of their development of the concept of local-regional resections combined modalities became publicized, traditional for treating cancers ofthe breast (Halsted, 1894), rectum surgical approaches were modified.
    [Show full text]